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Chronic hepatitis C virus (HCV) infection has been associated
with several extrahepatic disorders including autoimmune
thyroiditis, lichen planus and essential mixed cryoglobulinaemia.
These associations suggest that HCV may act as a trigger for the
development of various immune-mediated disorders. HCV is a
hepatotropic as well as a lymphotropic virus and can be respon-
sible not only for chronic liver disease but also for lymphoprolifer-
ative disorders (LPDs) (Pozzato et al, 1994). As a result of its
lymphotropic properties, HCV has been proposed as a possible
causative factor of essential mixed cryoglobulinaemia and may
trigger the monoclonal B-cell disorders such as non-Hodgkin’s
lymphoma (Zignego et al, 1992; Ferri et al, 1993). In this study we
investigated the prevalence of HCV in LPDs and compared it to
the donor population living in Southern Turkey.
MATERIALS AND METHODS
Serum samples taken before treatment in 228 patients with LPDs
were used as the study material. Non-Hodgkin’s lymphoma
(NHL), multiple myeloma (MM), Hodgkin’s disease (HD),
chronic lymphocytic leukaemia (CLL) and acute lymphoblastic
leukaemia (ALL) were present in 98, 47, 36, 38 and nine patients
respectively. The diagnoses were made according to diagnostic
criteria including histological confirmation of biopsy materials,
microscopic evaluation of peripheral blood and bone marrow
samples, biochemical parameters, and radiological findings. As a
control group, 36 226 donors were included in the study.
Antibodies against HCV were detected using the Third-
Generation ELISA kit (Abbott). Chi-square, Spearman rank
correlation, Mantel–Haenszel, Yates and Fisher’s exact tests were
used in order to assess the HCV risk.
Findings
The study group comprised 228 cases with LPDs. Anti-HCV anti-
bodies were positive in nine of 98 (9.18%) cases with NHL, five of
47 (10.63%) cases with MM, seven of 36 (19.44%) cases with HD,
four of 38 (10.52%) cases with CLL and one of nine (11.11%) cases
with ALL. Serum alanine aminotransferase levels were normal in
all except two of the seropositive patients. The characteristics of
the patients are shown in Table 1. Twenty-six of 228 (11.40%)
patients had antibody to HCV; anti-HCV prevalence in the donor
group was 0.53%. Anti-HCV antibody was found to be increased
in patients with LPDs as compared to the donor population
(P = 0.00000). A significant trend by age in anti-HCV positivity
was observed in the donor population (c2 trend 157, P < 0.000),
but a similar trend was not found among the patients (c2 0.93,
P = 0.76). HCV positivity in patient and donor groups is shown in
Table 2. Odds ratio (OR) for anti-HCV positivity was highest in
patients below 25 years of age, but was not significant in patients
older than 56 years of age as compared with the donor population
(Table 2). Among the seropositive NHL cases, six had low-grade
and three had high-grade lymphoma. T- and B-cell differentiation
was not conducted in this population, but in another study using
the same population T-cell phenotype was seen in 4% of the cases.
DISCUSSION
HCV is both a hepatotropic and a lymphotropic virus and it has
been proposed as a possible causative factor in some LPDs as well
as liver diseases. HCV-related antigens in infected patients have
been found in peripheral B and T lymphocytes, lymph nodes and
lymphocytes infiltrating the liver (Lai et al, 1998). The lymphotro-
pism of HCV suggests that this virus may be a trigger factor of the
clonal B-cell proliferation including essential mixed cryoglobulin-
aemia and malignant lymphoma (Zignego et al, 1992; Ferri et al,
1993)
The association between HCV infection and various LPDs has
been investigated in numerous studies. HCV-related lymphoma has
been reported from Italy, Japan, Israel and the USA (Izumi et al,
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prominent association between HCV and LPDs has been shown in
essential mixed cryoglobulinaemia and Waldenstrom macro-
globulinaemia. The prevalence of anti-HCV and/or HCV–RNA
positivity has been reported as between 42 and 100% (Agnello et
al, 1992; Santini et al, 1993; Ferri et al, 1993; Cacoub et al, 1994;
Pozzato et al, 1994; Mussini et al, 1995). In eight studies from
Italy, 25% of the patients (range 9–40%) with B-cell NHL were
positive for HCV antibodies (Ferri et al, 1994; Cavanna et al,
1995; Mazzuro et al, 1996; Pioltelli et al, 1996; Silvestri et al,
1996; Usto et al, 1996; Luppi et al, 1997; de Rosa et al, 1997).
In these studies, HCV positivity was much higher than in age-
comparable groups of the Italian population. In the study done by
Silvestri, anti-HCV antibodies were detected in the serum of 29 of
311 patients with B-cell NHL. In another study done by Izumi et al
(1996), anti-HCV was not detected in any case of non-B-cell NHL
and HD, whereas 12 of 54 (22.2%) cases of B-cell NHL were posi-
tive for HCV antibody. In three studies from the UK the evidence
of HCV infection using anti-HCV antibody and/or HCV–RNA
was not detected (Brind et al, 1996; Hanley et al, 1996; McColl et
al, 1996). In a study done by Musto et al (1996) the prevalence of
HCV as evaluated by both serological and/or molecular analysis in
a large group of LPDs, was found to be higher in 150 patients with
MM compared to the controls (12.6 vs 5.4%). However, this differ-
ence disappeared in patients over 50 years of age. We also found
that anti-HCV was not higher in patients older than 56.
Furthermore, in the study by Musto et al (1996), the prevalence of
anti-HCV was significantly higher than in controls and was inde-
pendent of age; we observed similar findings in our patients. It
would be more reliable and valuable if we could confirm our
results with HCV–RNA using polymerase chain reaction; another
study has been planned for this purpose. Our anti-HCV antibody
positivity is lower than in the Italian and higher than in the UK
populations. There remains a problem with HCV and LPD; despite
the epidemiological data about HCV, it has yet to be shown as an
aetiological factor of NHL. Reliable and easily performed HCV
in-situ detection techniques are, therefore, necessary (Lai et al,
1998).
At present, in some series there is insufficient evidence to
conclude that chronic HCV infection increases the risk of the
development of NHL, while in others it has been suggested that
HCV may play a direct pathogenetic role in some chronic LPDs.
The relationship between HCV and NHL remains uncertain in our
study. The striking geographical variation in the association
between NHL and HCV and pathogenetic role of HCV in lympho-
proliferation needs further investigations.
In the present study, OR for anti-HCV in the patients with LPDs
as compared to the donor population is 24.29. This suggests that
HCV infection may be a causative and/or contributing factor in
lymphoproliferation.
ACKNOWLEDGEMENT
We thank Prof Dr Esmeray Acartürk for her careful revision of the
manuscript.
REFERENCES
Agnello V, Chung RT and Kaplan LM (1992) A role for hepatitis C virus infection in
type II cryoglobulinemia. N Engl J Med 327: 1490–1495
Brind AM, Watson JP, Burt A, Kesteven P, Wallis J, Proctor SJ and Bassendine MF
(1996) Non-Hodgkin’s lymphoma and hepatitis C virus infection. Leuk
Lymphoma 21: 127–130
Cacoub P, Fabiani FL, Musset L, Perrin M, Franguel L, Leger M, Huraux JM, Pyette
JC and Godeau P (1994) Mixed cryoglobulinemia and hepatitis C virus. Am J
Med 96: 124–132
De Rosa G, Gobbo ML, Renzo A, Notaro R, Garofalo S, Grimaldi M, Apuzzo A,
Chiurazzi F, Picardi M, Matarazzo M and Rotoli B (1997) High prevalence of
hepatitis C virus infection in patients with B-cell lymphoproliferative disorders
in Italy. Am J Hematol 55: 77–82
Devita S, Zagonel V, Russo A, Rupolo M, Cannizzaro R, Chiara G, Boiocchi M,
Carbone A and Frenseschi S (1998) Hepatitis C virus, non-Hodgkin’s
lymphomas and hepatocellular carcinoma. Br J Cancer 77: 2032–2035
Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, Gentilini P,
Bombardieri S and Zignego AL (1993) Infection of peripheral blood
mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82:
3701–3704
Ferri C, Caracciolo F, Zignego AL, Civita LL, Monti M, Longombardo G,
Lombardini F, Greco F, Capochiani E, Mazzoni A, Mazzaro C and Pasero G
(1994) Hepatitis C infection in patients with non-Hodgkin’s lymphoma. Br J
Haematol 88: 392–394
Hanley J, Jarvis L, Simmonds P, Parker A and Ludiam C (1996) HCV and non-
Hodgkin’s lymphoma. Lancet 347: 1339
Izumi T, Sasaki R, Miura Y and Okamoto H (1996) Primary hepatosplenic
lymphoma: association with hepatitis C virus infection. Blood 87: 5380–5381
1304 S Paydas et al
British Journal of Cancer (1999) 80(9), 1303–1305 © 1999 Cancer Research Campaign 
Table 1 Anti-HCV positivity in patient groups
Disease Number Age range Mean age HCV (+) %
NHL 98 16–75 45±15 9 9.18
CLL 38 30–72 57±13 4 10.52
MM 47 33–85 60±10 5 10.63
HD 36 15–70 45±13 7 19.44
ALL 9 16–30 19±51 1 1 . 1 0
Total 228 15–85 51±16 26 11.40
NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukaemia; MM,
multiple myeloma; HD, Hodgkin’s disease.
Table 2 Anti-HCV positivity and OR in patients and donors by age groups
Donors Patients
Age HCV(+) HCV(–) % HCV(+) HCV(–) % OR (95% CI)
< 25 30 10237 0.29 4 22 15.38 62.04 (16.97–206.05)
26–35 58 19494 0.30 2 21 8.69 32.01 (invalid)
36–45 50 5107 0.97 3 32 8.57 9.58 (2.26–34.13)
46–55 42 1358 3.00 3 30 9.09 3.23 (0.75–11.69)
> 56 12 128 8.57 14 97 12.61 1.54 (0.64–3.74)
Total 192 36226 0.53 26 202 11.40 24.29 (15.38–38.10)Lai R and Weiss RM (1998) Hepatitis C virus and non-Hodgkin’s lymphoma. Am J
Clin Pathol 109: 508–510
Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, Morselli M,
Emilia G and Torelli G (1997) Prevalence of HCV infection and second
neoplasms in marginal zone lymphomas. Br J Haematol 96: 873–874
Mazzaro C, Zagonel V, Monfardini S, Tulissi P, Pussini E, Fanni M, Sorio R,
Bortolus R, Crovatto M, Santini G, Tiribelli C, Sasso F, Masutti R and Pozzato
G (1996) Hepatitis C virus and non-Hodgkin’s lymphomas. Br J Haematol 94:
544–550
McColl MD and Trait RC (1996) Hepatitis C virus infection in patients with
lymphoproliferative disorders. Br J Haematol 92: 771–772
Mussini C, Ghini M, Mascia MT, Giovanardi P, Zanni G, Lattudo I, Moreali S,
Longo G, Ferrari MG and Torelli G (1995) Monoclonal gammopathies and
hepatitis C virus infection. Blood 85: 1144–1145
Musto P, Dell’Olio M, Carotenuto M, Mangia A and Andriulli A (1996) Hepatitis C
virus infection: a new bridge between hematologists and gastroenterologists?
Blood 88: 752–753
Pioltelli P, Zehender G, Monti G, Monteverde A and Galli M (1996) HCV and non-
Hodgkin lymphoma. Lancet 347: 624–625
Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, Sulfaro S,
Franzin F, Tulissi P, Moretti M and Santini GF (1994) Low grade malignant
lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 84:
3047–3053
Santini GF, Crovatto M, Modolo ML, Martelli P, Silvia C, Mazzi G, Franzin F,
Moretti M, Tulissi P and Pozzato G (1993) Waldenstrom macroglobulinemia: a
role of HCV infection. Blood 82: 2932
Sikuler E, Shnaider A, Zilberman D, Hilzenrat N, Shemer-Avni Y, Neumann L and
Buskila D (1997) Hepatitis C virus infection and extrahepatic malignancies. 
J Clin Gastroenterol 24: 87–89
Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, Russo D, Ffalasca E,
Botta GA and Baccarani M (1996) Prevalence of hepatitis C virus infection in
patients with lymphoproliferative disorders. Blood 87: 4296–4301
Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E,
Romagnoni S, Gentilini P and Brechot C (1992) Infection of peripheral
mononuclear blood cells by hepatitis C virus. J Hepatol 15: 382–386
Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian
DG, Valenkar M, Nathwani BN and Fong TL (1997) Hepatitis C virus infection
in patients with B-cell non-Hodgkin’s lymphoma. Ann Intern Med 127: 423–428
HCV and lymphoproliferative disease 1305
British Journal of Cancer (1999) 80(9), 1303–1305 © 1999 Cancer Research Campaign